Free Trial

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 4 of 15

 
 

Corcept Therapeutics (NASDAQ:CORT)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$65.25 (24.0% Upside)

About Corcept Therapeutics

Corcept Therapeutics logoCorcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
10/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
10/18/2024Sandler O'NeillReiterated RatingBuy ➝ Buy
10/18/2024HC WainwrightBoost Price TargetBuy ➝ Buy$45.00 ➝ $80.00
9/30/2024Truist FinancialBoost Price TargetBuy ➝ Buy$65.00 ➝ $76.00
9/18/2024Piper SandlerBoost Price TargetOverweight ➝ Overweight$38.00 ➝ $67.00
7/30/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
7/30/2024HC WainwrightBoost Price TargetBuy ➝ Buy$40.00 ➝ $45.00
7/30/2024Piper SandlerBoost Price TargetOverweight ➝ Overweight$35.00 ➝ $38.00
7/1/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$35.00 ➝ $35.00
6/17/2024Truist FinancialReiterated RatingBuy ➝ Buy$65.00 ➝ $65.00
 

📉 Warning: Market Crash Predicted - Secure Your Savings (Ad)

The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.

Take these 4 steps to protect your retirement here >>>